535 related articles for article (PubMed ID: 8652851)
1. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
2. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
Johnson BD; Truitt RL
Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
[TBL] [Abstract][Full Text] [Related]
3. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
4. Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
Drobyski WR; Morse HC; Burns WH; Casper JT; Sandford G
Blood; 2001 Apr; 97(8):2506-13. PubMed ID: 11290616
[TBL] [Abstract][Full Text] [Related]
5. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin.
Blazar BR; Carroll SF; Vallera DA
Blood; 1991 Dec; 78(11):3093-102. PubMed ID: 1954395
[TBL] [Abstract][Full Text] [Related]
6. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
Drobyski WR; Majewski D
Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343
[TBL] [Abstract][Full Text] [Related]
7. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
8. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
9. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
10. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Vallera DA
Blood; 1995 May; 85(9):2607-18. PubMed ID: 7537122
[TBL] [Abstract][Full Text] [Related]
11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
12. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
Truitt RL; Atasoylu AA
Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.
Gorczynski RM; Chen Z; Zeng H; Gorczynski L; Terzioglu E
Immunology; 1998 Feb; 93(2):221-9. PubMed ID: 9616372
[TBL] [Abstract][Full Text] [Related]
14. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Barrett TA; Bluestone JA; Vallera DA
Blood; 1996 Jan; 87(2):827-37. PubMed ID: 8555509
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
16. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
Koch U; Korngold R
Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
[TBL] [Abstract][Full Text] [Related]
17. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR
Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
[TBL] [Abstract][Full Text] [Related]
19. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens.
Blazar BR; Taylor PA; Bluestone JA; Vallera DA
Blood; 1996 May; 87(10):4463-72. PubMed ID: 8639809
[TBL] [Abstract][Full Text] [Related]
20. Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299.
Annat J; Churaqui E; Dutartre P; Bruley-Rosset M
Transplantation; 1996 Sep; 62(6):721-9. PubMed ID: 8824467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
